Thus, the treatments aimed at the inhibition of NF-κB and MAPKs, as well as the direct inhibition of oxidative stress, may have potential therapeutic advantages in curing ALI/ARDS. The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.